Pursuant to Regulation 30 of the Listing Regulations, please find attached Press Release titled- Indian Drug Regulator Approves Wockhardt''s New Generation Oral Antibiotic MiqnafR (Nafithromycin) for ...

Drugmaker Wockhardt has got off to an optimistic start this year with its novel antibiotic nafithromycin (Miqnaf) getting regulatory approval from the Central Drugs Standard Control Organization.

Pharmaceuticals firm Wockhardt Ltd on Thursday (January 2) announced that the Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for ...

Shares of Wockhardt, the pharmaceutical and biotechnology major, spiked 9.5% in early trade on Friday, January 3, to hit a nine-year high of ₹1,583 apiece after the company announced regulatory ...

Shares of Wockhardt are higher by 5% on January 3 after Indian drug regulator approved oral antibiotic for the treatment of Pneumonia, the company informed in an exchange filing. Central Drugs ...

Drugmaker Wockhardt on Thursday announced Central Drugs Standard Control Organization (CDSCO) approval for use of its new generation oral antibiotic Miqnaf (Nafithromycin) in the treatment of ...

Shares of Wockhardt Ltd. are trading with gains of as much as 10% on Friday, January 3. The uptick in the stock price was seen after Wockhardt informed the exchanges that Indian drug regulator, ...

Wockhardt shares rose 5.4 per cent in Friday's trade on BSE and hit 52-week high at Rs 1,580 per share. The buying interest in the stock can be attributed to company receiving Indian Drug Regulator's ...